157 E 32nd St. New York, NY 10016 212-689-6791

Welcome to the InformCLL Study at MHOA

Now enrolling patients for the InformCLL Registry. The purpose of the InformCLL Registry is to characterize and describe treatment patterns for those initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL /SLL therapies/regimens.

This study also evaluates association of treatment patterns with patient characteristics, healthcare resource utilization and patient reported Health related Quality of Life (HRQoL).

MHOA Principle Investigator
Alec Goldenberg, M.D. 

For additional information contact:
Phenoia Browne, Clinical Trials Coordinator
Phone: 212-689-6791 ext 228
Email: clinicaltrials@mhony.com

AML- FLT3

Now enrolling of patients on a phase 2/3 clinical study for the treatment of AML patients with FLT3 mutations who are…

Read More

AML- FLT3/IDT

Now enrolling patients for a phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215)…

Read More

Mantle Cell Lymphoma

Now enrolling patients in a phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of…

Read More

Hodgkin Lymphoma

The objectives of this molecular profiling protocol are to describe current treatment patterns and consequences from first-line treatment

Read More